Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 15,400 Shares

Posted by Brian Himes on Apr 17th, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 15,400 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $11.67, for a total value of $179,718.00. Following the transaction, the insider now directly owns 3,078,916 shares in the company, valued at approximately $35,930,949.72. This represents a 0.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Thursday, April 10th, Saba Capital Management, L.P. sold 30,156 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.14, for a total transaction of $335,937.84.
On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.57, for a total transaction of $79,705.73.
On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.28, for a total transaction of $357,372.56.
On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.01, for a total value of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.62, for a total value of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.75, for a total value of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total value of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total transaction of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total transaction of $216,090.61.

Abrdn Life Sciences Investors Stock Performance

Shares of HQL stock opened at $11.68 on Thursday. The company’s 50-day simple moving average is $12.91 and its two-hundred day simple moving average is $13.76. Abrdn Life Sciences Investors has a one year low of $10.55 and a one year high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Friday, February 21st were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, February 21st. This represents a $1.88 annualized dividend and a yield of 16.10%.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

A number of institutional investors and hedge funds have recently bought and sold shares of HQL. BankPlus Trust Department purchased a new position in shares of Abrdn Life Sciences Investors during the fourth quarter valued at $28,000. Steward Partners Investment Advisory LLC increased its position in Abrdn Life Sciences Investors by 379.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock valued at $64,000 after purchasing an additional 3,847 shares during the period. Wealthcare Advisory Partners LLC purchased a new position in Abrdn Life Sciences Investors during the 1st quarter valued at about $131,000. Landscape Capital Management L.L.C. bought a new stake in shares of Abrdn Life Sciences Investors in the 4th quarter valued at about $154,000. Finally, Kingswood Wealth Advisors LLC purchased a new stake in shares of Abrdn Life Sciences Investors in the 4th quarter worth approximately $160,000. 32.21% of the stock is owned by institutional investors.

Abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.